CYT Dividend History & Description — Cyteir Therapeutics Inc
Cyteir Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing the oncology medicines that inhibit deoxyribonucleic acid damage repair and cause cancer cell death in specific subsets of cancer patients through a therapeutic strategy known as synthetic lethality. Co.'s primary program, CYT-0851, was identified through a phenotypic screening strategy that exploited a synthetic lethality between cytidine deaminases (CD) overexpression and homologous recombination inhibition. The screen was designed to select for compounds that induced synthetic lethality in CD-overexpressing cancer cells while sparing normal cells. When considering the Cyteir Therapeutics Inc stock dividend history, we have taken known splits into account, such that the CYT dividend history is presented on a split-adjusted ("apples to apples") basis. Cyteir Therapeutics Inc dividend history is presented both in graphical/chart form, and as a CYT dividend history data table along the right-hand column.